2016, Number 3
<< Back Next >>
Arch Neurocien 2016; 21 (3)
Glutamato para principiantes
Avila RH, Pérez NI
Language: Spanish
References: 21
Page: 25-28
PDF size: 185.00 Kb.
Text Extraction
No abstract.
REFERENCES
European Food Information Council. 2002. Datos fiables sobre el glutamato monosódico. Disponible en: http://www.eufic.org/article/es/artid/glutamato-monosodico/ Accesado el 6 de julio 2016.
Schab L. 2015. Glutamato, la nicotina alimentaria. Disponible en: http://www.caminosalser.com/1028-alimentacion-consciente/glutamato-la-nicotina-alimentaria/ Accesado el 7 de julio 2016.
Línea y salud. 2009. Disponible en: http://www.lineaysalud.com/nutricion/alimentos/glutamato-monosodico Accesado el 9 de julio 2016.
Blaylock, RL. Excitoxins: The taste that Kills. Santa Fe: Health Press, 1994.
Millan MJ. N-methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 2005;179:30-53.
Marx MC, Billups D, Billups B. Maintaining the presynaptic glutamate supply for excitatory neurotramission. J Neurosci Res 2015;93:1031-44.
Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm 2014; 121: 799-817.
Shang LH, Luo ZQ, Deng XD, Wang MJ, Huang FR, Feng DD, Yue SJ. Expression of N-methyl-D-aspatate receptor and its effect on nitric oxide production of rat alveolar macrophages. Nitric Oxide 2010;23:327-31.
Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling Pathways. Int J Biol Sci 2013;9: 948-59.
Benes MF. Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else? Biol Psychiatry 2009;65:1003-5.
Tuominen HJ, Tiihonen J, Wahlbeck. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005;72:225-34.
Chaki S. Group II: metabotropic glutamate receptor agonists as a potential drug for schizophrenia. Eur J Pharmacol 2010;639: 59-66.
Novelli A, Pérez BM, Fernández SMT. Glutamate and neurodegeneration. En: Schmidt WJ, Reith MEA, Eds.Dopamine and glutamate in psychiatric disorders. Nueva Jersey: Humana Press; 2005.
Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26: 365-84.
Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia.Pharmacol Biochem Behav 2012;100:665-77.
Kantrowitz JT, Javitt DC. N-methyl-D-aspartate (NMDA) receptor dysfunction o dysregulation: the final common pathway on the road to Schizophrenia? Brain Res Bull 2010;83:108-21.
Labrie V, Roder JC. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of Schizophrenia. Neurosci Biobehav Rev 2010;34:351-72.
Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatr 2000;157:1141–9.
Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine lutamate interactions. Int Rev Neurobiol 2007;78:69-108.
Gregory KJ, Noetzel MJ, Niswender CM. Pharmacology of metabotropic glutamate receptor allosteri modulators: structural basis and therapeutic potential for CNS disorders. Prog Mol Biol Transl Sci 2013; 115: 61-121.
Paz RD, Tardito S, Atzori M, Tseng KY. Glutamatergic dysfunction in schizophrenia: from basic neurocience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008;18:773-86.
Full text